Zumutor Biologics
Zumutor: A leading Immuno-Oncology firm innovating NK cell therapies and novel immunotherapies.
Founded
2015Zumutor: A leading Immuno-Oncology firm innovating NK cell therapies and novel immunotherapies.
Zumutor Biologics, founded in 2015, is a pioneering Immuno-Oncology company specializing in targeted NK cell therapeutics. With a mission to innovate and develop novel immunotherapies, Zumutor leverages two proprietary Antibody Engineering Platforms to enhance innate immunity and regulate the tumor microenvironment. Their flagship platform, INABLR™, generates first-in-class therapeutic antibodies aimed at combating cancer. The company operates from its headquarters at CIC Cambridge Campus in Cambridge, MA, USA, and maintains an ISO-certified laboratory in Bangalore, India.
Notable figures associated with Zumutor include its CEO and founder, Kavitha Iyer Rodrigues. The company has attracted significant investment from prominent venture capital firms such as Bharat Innovation Fund and Accel Partners. Key achievements include the development of multiple first-in-class therapeutic antibodies and securing several patents for their proprietary technologies. Zumutor's impact is evident in its contributions to advancing cancer treatment through innovative NK cell therapies, positioning it as a leader in the Immuno-Oncology space.
Companies similar to Zumutor Biologics include Modulus Therapeutics, Meditope Biosciences, Numab and Torl Biotherapeutics.
Zumutor Biologics was founded in 2015.
Zumutor Biologics' headquarters is located in Bangalore, Karnataka, IN.
Zumutor Biologics' most recent funding round was for $6.2M (USD) in December 2021.
As of Dec 9, 2021, Zumutor Biologics has disclosed funding of $47.8M (USD). Undisclosed round amounts are excluded.
Zumutor Biologics has 29 employees as of Feb 4, 2024.
Torl Biotherapeutics
torlbio.com
